CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
The firm says its Olerup QType test is available on both Roche and Applied Biosystems platforms.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.